Literature DB >> 17623048

Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.

Xianting Li1, Yin-Cai Tan, Shibu Poulose, C Warren Olanow, Xin-Yun Huang, Zhenyu Yue.   

Abstract

Mutations in Leucine-rich repeat kinase 2 (LRRK2) are linked to the most common familial forms and some sporadic forms of Parkinson's disease (PD). The LRRK2 protein contains two well-known functional domains, MAPKKK-like kinase and Rab-like GTPase domains. Emerging evidence shows that LRRK2 contains kinase activity which is enhanced in several PD-associated mutants of LRRK2. However, the GTPase activity of LRRK2 has yet to be formally demonstrated. Here, we produced and purified the epitope-tagged LRRK2 protein from transgenic mouse brain, and showed that purified brain LRRK2 possesses both kinase and GTPase activity as assayed by GTP binding and hydrolysis. The brain LRRK2 is associated with elevated kinase activity in comparison to that from transgenic lung or transfected cultured cells. In transfected cell cultures, we detected GTP hydrolysis activity in full-length as well as in GTPase domain of LRRK2. This result indicates that LRRK2 GTPase can be active independent of LRRK2 kinase activity (while LRRK2 kinase activity requires the presence of LRRK2 GTPase as previously shown). We further found that PD mutation R1441C/G in the GTPase domain causes reduced GTP hydrolysis activity, consistent with the altered enzymatic activity in the mutant LRRK2 carrying PD familial mutations. Therefore, our study shows the biochemical characteristics of brain-specific LRRK2 which is associated with robust kinase and GTPase activity. The distinctive levels of kinase/GTPase activity in brain LRRK2 may help explain LRRK2-associated neuronal functions or dysfunctions in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623048      PMCID: PMC2827244          DOI: 10.1111/j.1471-4159.2007.04743.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  BAC to the future: the use of bac transgenic mice for neuroscience research.

Authors:  N Heintz
Journal:  Nat Rev Neurosci       Date:  2001-12       Impact factor: 34.870

Review 2.  Roc, a Ras/GTPase domain in complex proteins.

Authors:  Leonard Bosgraaf; Peter J M Van Haastert
Journal:  Biochim Biophys Acta       Date:  2003-12-07

3.  Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain.

Authors:  C L Farnsworth; M S Marshall; J B Gibbs; D W Stacey; L A Feig
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

4.  Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome.

Authors:  X W Yang; P Model; N Heintz
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

5.  The identification and characterization of an epidermal growth factor-stimulated phosphorylation of a specific low molecular weight GTP-binding protein in a reconstituted phospholipid vesicle system.

Authors:  M J Hart; P G Polakis; T Evans; R A Cerione
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

6.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

7.  Interaction of Rac1 with GTPase-activating proteins and putative effectors. A comparison with Cdc42 and RhoA.

Authors:  B Zhang; J Chernoff; Y Zheng
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

8.  GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins.

Authors:  Chunzhi Xia; Wenbin Ma; Lewis Joe Stafford; Chengyu Liu; Liming Gong; James F Martin; Mingyao Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

Review 9.  The Rab GTPase family.

Authors:  H Stenmark; V M Olkkonen
Journal:  Genome Biol       Date:  2001-04-27       Impact factor: 13.583

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  127 in total

1.  Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC.

Authors:  Arjan Kortholt; Wouter N van Egmond; Katarzyna Plak; Leonard Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2011-11-26       Impact factor: 5.157

2.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

3.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

4.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

5.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

6.  The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

Authors:  Lizhen Wang; Chengsong Xie; Elisa Greggio; Loukia Parisiadou; Hoon Shim; Lixin Sun; Jayanth Chandran; Xian Lin; Chen Lai; Wan-Jou Yang; Darren J Moore; Ted M Dawson; Valina L Dawson; Gabriela Chiosis; Mark R Cookson; Huaibin Cai
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

Review 7.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

8.  Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system.

Authors:  Jie Cui; Mei Yu; Jingwen Niu; Zhenyu Yue; Zhiheng Xu
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

9.  The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration.

Authors:  Cherry Cheng-Ying Ho; Hardy J Rideout; Elena Ribe; Carol M Troy; William T Dauer
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

10.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.